Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.

Fangwen ZhangLing LiLei ZhangXin LiXiaorui FuXinhua WangJingjing WuZhenchang SunFei KongLiangliang RenMingzhi Zhang

Published in: Blood and lymphatic cancer : targets and therapy (2019)

Our retrospective study shows that CD5+ has a poorer prognosis than CD5- patients. Based on its improved lifetime and good tolerance on CD5+ patients, which is expected to become the first-line treatment for high-risk DLBCL types based on more clinical research.

Keyphrases

diffuse large b cell lymphoma
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
epstein barr virus
randomized controlled trial
peritoneal dialysis
systematic review
prognostic factors
poor prognosis
nk cells
patient reported outcomes
long non coding rna